Showing results (531-540 of 776) with videos related to
Sort By:
Pageof 78
Journal of Drugs in Dermatology : JDD|June 5, 2023
Integrating Precision Medicine into Medical Dermatology Clinical Practice: An Expert Consensus PanelDanny Zakria, Nicholas Brownstone, April W Armstrong, et al.Journal of the American Academy of Dermatology|March 6, 2024
Mental health outcomes in patients with moderate to severe psoriasis treated with bimekizumab: Analysis of phase 2/3 randomized trialsAndrew Blauvelt, April Armstrong, Joseph F Merola, et al.International Journal of Dermatology|April 14, 2015
A consensus approach to improving patient adherence and persistence with topical treatment for actinic keratosisEggert Stockfleth, Ketty Peris, Carlos Guillen, et al.Advances in Therapy|September 23, 2020
PSO-LONG: Design of a Novel, 12-Month Clinical Trial of Topical, Proactive Maintenance with Twice-Weekly Cal/BD Foam in PsoriasisLinda Stein Gold, Javier Alonso-Llamazares, Jean-Philippe Lacour, et al.Journal of Managed Care & Specialty Pharmacy|April 27, 2026
AMCP Market Insights: Beyond skin deep on the role of managed care in moderate to severe atopic dermatitisBridget Flavin, Denise Wolff, Mike Abdo, et al.BMJ Open|April 22, 2019
Impact of psoriasis severity on patient-reported clinical symptoms, health-related quality of life and work productivity among US patients: real-world data from the Corrona Psoriasis RegistryBruce Strober, Jeffrey D Greenberg, Chitra Karki, et al.American Journal of Clinical Dermatology|August 7, 2022
Switching Between Adalimumab Reference Product and BI 695501 in Patients with Chronic Plaque Psoriasis (VOLTAIRE-X): A Randomized Controlled TrialAlan Menter, Stanley Cohen, Jonathan Kay, et al.Journal of Drugs in Dermatology : JDD|September 20, 2005
A large 12-month extension study of an 8-week trial to evaluate the safety and efficacy of triple combination (TC) cream in melasma patients previously treated with TC cream or one of its dyadsHelen Torok, Susan Taylor, Leslie Baumann, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|January 5, 2024
Efficacy of long-term risankizumab treatment for moderate-to-severe plaque psoriasis: Subgroup analyses by baseline characteristics and psoriatic disease manifestations through 256 weeks (LIMMitless trial)Bruce Strober, Hervé Bachelez, Jeffrey Crowley, et al.Journal of Drugs in Dermatology : JDD|October 14, 2015
Anti-IL-23 Phase II Data for Psoriasis: A ReviewKourosh Beroukhim, Melissa J Danesh, Catherine Nguyen, et al.Pageof 78